hydrOXYzine Hydrochloride Oral Solution, 10 mg/5 mL recall — Ani Pharmaceuticals, Inc. (Class III)
Ani Pharmaceuticals, Inc. is recorded by the U.S. Food and Drug Administration (FDA) as recalling hydrOXYzine Hydrochloride Oral Solution, 10 mg/5 mL — a Class III recall, initiated 2026-06-02 and posted to the FDA enforcement report on 2026-07-01, under recall number D-0619-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Presence of foreign substance”. From the product description, the form is oral solution, the strengths given are 10 mg/5 mL and 473 mL and it is marked Rx only. 1 National Drug Code number is printed in the record: 70954-912-10. Distribution is recorded as “Nationwide in the USA” — Nationwide (US), with the recalling firm on record in MN, United States. It is the only recall number the FDA has filed under event ID 99131. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.
Regulatory snapshot
| Recall number | D-0619-2026 |
|---|---|
| FDA event ID | 99131 |
| Classification | Class III (least serious regulatory tier) |
| Status | Ongoing |
| Recalling firm | Ani Pharmaceuticals, Inc. |
| Recall initiated | 2026-06-02 |
| Reported by FDA | 2026-07-01 |
| Report lag | 29 days from initiation to report |
| Distribution | Nationwide in the USA — Nationwide (US) |
| Firm location on record | MN, United States |
| Product description (source) | hydrOXYzine Hydrochloride Oral Solution, USP, 10 mg/5 mL, 473 mL (1 Pint), Rx only, Distributed by: ANI Pharmaceuticals, Inc., Baudette, MN 56623. NDC: 70954-912-10 |
Reason reported by FDA
Presence of foreign substance
4 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.
Product identifiers in this record
6 identifying values matched by exact pattern in the 24-word product description above; each is a literal substring of it.
| Product named | hydrOXYzine Hydrochloride Oral Solution |
|---|---|
| Form | Oral Solution |
| Strength | 10 mg/5 mL · 473 mL |
| NDC | 70954-912-10 |
| Marketing category | Rx only |
| Distributed by | ANI Pharmaceuticals, Inc. |
Other indexed recalls from Ani Pharmaceuticals, Inc.
2 indexed records name Ani Pharmaceuticals, Inc. as the recalling firm, across 2 FDA events, reported 2026-05-27 to 2026-07-01. A coverage-limited activity count over the ingested window, not a quality rating.
| Recall record | Recall number | FDA tier | Strength / form | Reported |
|---|---|---|---|---|
| Estradiol Gel, 0.1% | D-0543-2026 | Class II | 0.1% · Gel | 2026-05-27 |
Reported in the same month (2026-07)
111 enforcement reports carry a report date in 2026-07; these 4 are the Class III ones nearest this record.
| Recall record | Recall number | Recalling firm | FDA tier | Reported |
|---|---|---|---|---|
| Fexofenadine Hydrochloride Tablets, 180 mg | D-0654-2026 | Sun Pharmaceutical Industries Inc | Class III | 2026-07-08 |
| Lidolog Kit, 2% | D-0713-2026 | Asclemed Usa Inc. | Class III | 2026-07-29 |
| Dabigatran etexilate Capsules, 110 mg | D-0735-2026 | Ascend Laboratories, LLC | Class III | 2026-07-29 |
| Dabigatran etexilate Capsules, 150 mg | D-0736-2026 | Ascend Laboratories, LLC | Class III | 2026-07-29 |
Nearest Class III recalls by date
25 of 250 indexed records share the Class III tier; the 10 nearest to 2026-07-01 by report date are listed here.
| Recall record | Recall number | Recalling firm | Strength / form | Reported |
|---|---|---|---|---|
| Focalin XR (dexmethylphenidate HCl) 5 mg | D-0608-2026 | Sandoz Inc | 5 mg · Extended-Release Capsules | 2026-06-24 |
| Epinephrine Injection, 1mg/mL | D-0581-2026 | Fresenius Kabi Usa, LLC | 1mg/mL · Injection | 2026-06-17 |
| Primidone Tablets, 50 mg | D-0585-2026 | Amneal Pharmaceuticals, LLC | 50 mg · Tablets | 2026-06-17 |
| Lidocaine HCl Injection, 2% | D-0552-2026 | Eugia US LLC | 2% · Injection | 2026-06-10 |
| Nicotine Transdermal System Patch, 14 mg | D-0550-2026 | Aveva Drug Delivery Systems, Inc. | 14 mg · Transdermal System | 2026-06-03 |
| PRED MILD, 0.12% | D-0551-2026 | Abbvie Inc. | 0.12% · Ophthalmic Suspension | 2026-06-03 |
| Primidone Tablets USP, 250mg | D-0533-2026 | Lannett Company Inc. | 250mg · Tablets | 2026-05-27 |
| Primidone Tablets, 50 mg | D-0534-2026 | Golden State Medical Supply Inc. | 50 mg · Tablets | 2026-05-27 |
| Primidone Tablets, 250 mg | D-0535-2026 | Golden State Medical Supply Inc. | 250 mg · Tablets | 2026-05-27 |
| Primidone Tablets, 250 mg | D-0536-2026 | Amerisource Health Services LLC | 250 mg · Tablets | 2026-05-27 |
Reading this record
Class III is the FDA's own severity tier for the recall action — 25 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 70954-912-10 at the FDA source to confirm it is covered.
Namespace context: the Class III index (25 records) and the recall hub (250 records, 118 FDA events); Ani Pharmaceuticals, Inc. (2 indexed records) aggregates this firm across datasets.
Coverage and limits of this record
This page reflects the openFDA enforcement report for D-0619-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.
Source & provenance
- Official source
- https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0619-2026%22
- Source dataset
- openFDA Drug Enforcement API
- Publication date
- 2026-07-01
- Ingested
- 2026-08-22
- Record hash
2d47154902ab1c08
Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.